This study aimed to explore the prevalence and safety of SARS-CoV-2 vaccination in individuals with dementia. Patients with mild cognitive impairment or dementia were recruited at a tertiary memory clinic, from March 15 to September 15, 2021. Information on COVID-19 vaccination and adverse events experienced after vaccine administration were collected from caregivers. Two-hundred-seventy subjects were finally recruited. Among them, 253 (93.7%) had received the vaccine and only 69 (27.3%) experienced adverse events. Cognitive and behavioral changes following immunization were only rarely reported. COVID-19 vaccination is safe and well-tolerated in patients with cognitive impairment who should be prioritized in the vaccination campaign.

Prevalence and Safety of COVID-19 Vaccination in Community-Dwelling People with Dementia: Findings from a Tertiary Memory Clinic in Italy / Valletta, Martina; Canevelli, Marco; D'Antonio, Fabrizia; Trebbastoni, Alessandro; Talarico, Giuseppina; Campanelli, Alessandra; SEPE MONTI, Micaela; DI VITA, Antonella; Salati, Emanuela; Imbriano, Letizia; Margiotta, Roberta; Barbetti, Sonia; Diana, Sofia; Buscarnera, Simona; TOCCACELI BLASI, Marco; Salzillo, Martina; Pugliese, Giuseppe; Vanacore, Nicola; Bruno, Giuseppe. - In: JOURNAL OF ALZHEIMER'S DISEASE. - ISSN 1387-2877. - (2022).

Prevalence and Safety of COVID-19 Vaccination in Community-Dwelling People with Dementia: Findings from a Tertiary Memory Clinic in Italy.

Martina Valletta;Marco Canevelli;Fabrizia D'Antonio;Giuseppina Talarico;Micaela Sepe Monti;Antonella Di Vita;Emanuela Salati;Roberta Margiotta;Sonia Barbetti;Sofia Diana;Simona Buscarnera;Marco Toccaceli Blasi;Martina Salzillo;Nicola Vanacore;Giuseppe Bruno
2022

Abstract

This study aimed to explore the prevalence and safety of SARS-CoV-2 vaccination in individuals with dementia. Patients with mild cognitive impairment or dementia were recruited at a tertiary memory clinic, from March 15 to September 15, 2021. Information on COVID-19 vaccination and adverse events experienced after vaccine administration were collected from caregivers. Two-hundred-seventy subjects were finally recruited. Among them, 253 (93.7%) had received the vaccine and only 69 (27.3%) experienced adverse events. Cognitive and behavioral changes following immunization were only rarely reported. COVID-19 vaccination is safe and well-tolerated in patients with cognitive impairment who should be prioritized in the vaccination campaign.
File allegati a questo prodotto
File Dimensione Formato  
Valletta_Prevalence and Safety of COVID-19 Vaccination_2022.pdf

solo gestori archivio

Tipologia: Documento in Pre-print (manoscritto inviato all'editore, precedente alla peer review)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 257.86 kB
Formato Adobe PDF
257.86 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1634346
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact